m+Medelevator.RU
← Поиск публикаций
Journal of microbiology and biotechnology · 2025

Fermented Protaetia brevitarsis Larvae Alleviates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in C57BL/6 Mice via Regulation of Lipid Accumulation and Inflammation.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Lee Hyo Lim, Kim Jong Min, Go Min Ji, Lee Han Su, Kim Ju Hui, Kim In Young, Seong Geum-Su, Heo Ho Jin

Аннотация

Non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis and hepatitis, is the most frequently encountered complication of type 2 diabetes mellitus (T2DM). Due to its hepatoprotective, anti-obesity, antioxidant, and anti-inflammatory effects, Protaetia brevitarsis (P. brevitarsis) larvae have been used as traditional medicine to treat liver diseases since ancient times. Therefore, this study was conducted to confirm the positive effect of fermented P. brevitarsis larvae (FPB) on NAFLD. The results showed that high-fat diet (HFD)-induced dysglycemia was improved by treatment with FPB as determined by testing for fasting blood glucose and oral glucose tolerance. The weight of liver and white adipose tissue and the levels of serum lipid, hepatotoxicity, and nephrotoxicity indicators were reduced by FPB. In addition, oxidative stress and mitochondrial dysfunction caused by HFD were improved by FPB. In a similar manner, HFD-induced hepatic steatosis was prevented by FPB through regulation of the AMP-activated protein kinase pathway and serum lipid profile. HFD-induced hepatitis and apoptosis were ameliorated by FPB via the nuclear factor-kappa B pathway and the B-cell lymphoma 2 protein family. In conclusion, this study suggests the potential for application of FPB as a prophylactic agent for treatment of NAFLD through suppression of lipid accumulation and inflammation in the liver.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты